Melatonin and Eye Health: What Clinical Trials Show About AMD and Retinal Repair
Written by Dr. Louis Michaelos, Ophthalmologist & Founder, MacuRest | Last reviewed May 2026
Clinical trial data shows melatonin has potent antioxidant activity in retinal tissue, and a landmark 2024 study in JAMA Ophthalmology found melatonin users had significantly lower AMD progression rates across 100,000+ patients. Preliminary controlled trials show stabilization of macular function in AMD patients taking nightly melatonin over 24 months.
Why Researchers Are Looking at Melatonin and the Eye
Melatonin is also produced directly by the retina — a fact driving growing scientific interest in its role in eye health. Retinal melatonin peaks at night and directly regulates overnight photoreceptor maintenance.
Melatonin as a Retinal Antioxidant
Melatonin and its metabolites directly neutralize reactive oxygen species in retinal cells. Research in Ophthalmic Research found melatonin reduced oxidative stress markers in RPE cells exposed to light-induced damage.
Melatonin Levels and AMD Risk
AMD patients have measurably lower circulating melatonin than age-matched controls. A study in Current Eye Research reported significantly reduced urinary melatonin metabolites in advanced AMD patients — suggesting melatonin is physiologically connected to disease progression, not merely a bystander.
The 2024 JAMA Ophthalmology Study
A large observational study published in JAMA Ophthalmology (2024) analyzed 100,000+ patient records. Melatonin users were significantly less likely to progress to late-stage AMD — particularly notable in patients also taking AREDS-type supplements.
Pilot Trials on Supplementation
A clinical trial in the Annals of the New York Academy of Sciences examined 3mg nightly melatonin in AMD patients. Participants showed stabilization of macular function over 24 months. The study was small, but prompted interest in larger trials. Melatonin is not a replacement for the NEI-validated AREDS2 formula — it complements it.
Why Evening Timing Matters
The RPE performs its most critical maintenance work overnight. Taking a supplement combining AREDS2 with melatonin in the evening means both elements are circulating during peak retinal repair activity. This is the rationale behind MacuRest. Learn more: How MacuRest works | Why evening timing matters | Evening eye vitamins
Frequently Asked Questions
What do clinical trials show about melatonin and eye health?
The strongest evidence is a 2024 JAMA Ophthalmology study of 100,000+ patients showing significantly lower AMD progression rates in melatonin users. Pilot trials show stabilization of macular function with nightly melatonin over 24 months. Melatonin has potent antioxidant activity in retinal tissue and AMD patients consistently show lower melatonin levels than healthy controls.
How does melatonin act as a retinal antioxidant?
Melatonin and its metabolites directly neutralize reactive oxygen species in retinal pigment epithelium cells — the same oxidative damage that drives AMD progression. Research in Ophthalmic Research found melatonin reduced oxidative stress markers in RPE cells exposed to light-induced damage. This antioxidant function is separate from melatonin's role as a sleep hormone.
Why do AMD patients have lower melatonin levels?
AMD patients consistently show lower circulating and urinary melatonin metabolites than age-matched controls without AMD. The mechanism is not fully understood, but lower retinal melatonin may impair the overnight photoreceptor renewal cycle — contributing to progressive photoreceptor damage. This is one reason melatonin supplementation is being investigated as a complement to AREDS2.
Does melatonin replace AREDS2 for macular degeneration?
No. The AREDS2 six-nutrient formula has substantially more clinical evidence than melatonin for AMD specifically — a 4,200-patient randomized controlled trial vs. observational data and small pilot studies. Melatonin is best considered a complement to the AREDS2 formula that may address the overnight repair window AREDS2 doesn't target. MacuRest combines both.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.